Cargando…

Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

Detalles Bibliográficos
Autores principales:	Recourt, Kasper, de Boer, Peter, Zuiker, Rob, Luthringer, Remy, Kent, Justine, van der Ark, Peter, Van Hove, Ilse, van Gerven, Joop, Jacobs, Gabriel, van Nueten, Luc, Drevets, Wayne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775147/ https://www.ncbi.nlm.nih.gov/pubmed/31578318 http://dx.doi.org/10.1038/s41398-019-0585-4

Ejemplares similares

The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
por: Recourt, Kasper, et al.
Publicado: (2019)

Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder
por: Recourt, Kasper, et al.
Publicado: (2023)

Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
por: Salvadore, Giacomo, et al.
Publicado: (2020)

Characteristics of Seltorexant—Innovative Agent Targeting Orexin System for the Treatment of Depression and Anxiety
por: Ziemichód, Wojciech, et al.
Publicado: (2023)

The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study
por: Schmidt, Mark E., et al.
Publicado: (2020)

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
por: Morrison, Randall L., et al.
Publicado: (2018)

Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant
por: Jha, Manish Kumar
Publicado: (2021)

Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study
por: Savitz, Adam, et al.
Publicado: (2021)

Fatty Acid Amide Hydrolase Inhibition by JNJ‐42165279: A Multiple‐Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers
por: Postnov, Andrey, et al.
Publicado: (2018)

Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor
por: Timmers, Maarten, et al.
Publicado: (2016)

Effects of the selective orexin-2 receptor antagonist JNJ-48816274 on sleep initiated in the circadian wake maintenance zone: a randomised trial
por: Revell, Victoria L., et al.
Publicado: (2021)

The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study
por: van de Loo, Aurora J. A. E., et al.
Publicado: (2017)

Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation
por: Bonaventure, Pascal, et al.
Publicado: (2017)

PS202. The regulation of orexins and their cognate receptors in two distinct rat models of depression and effects of treatments
por: Harpøth, Astrid, et al.
Publicado: (2016)

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
por: Timmers, Maarten, et al.
Publicado: (2018)

Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers
por: Dijkstra, Francis, et al.
Publicado: (2022)

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
por: Novak, Gerald, et al.
Publicado: (2020)

FHH Quick App Review: How Can a Quality Review Process Assist Primary Care Providers in Choosing a Family Health History App for Patient Care?
por: Wood, Grant M., et al.
Publicado: (2022)

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection
por: Bourgeois, Stefan, et al.
Publicado: (2017)

Does Orexin B-Binding Receptor 2 for Orexins Regulate Testicular and Epididymal Functions in Normal and Cryptorchid Dogs?
por: Squillacioti, Caterina, et al.
Publicado: (2022)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2021)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
por: Konings, I R H M, et al.
Publicado: (2010)

Znf202 Affects High Density Lipoprotein Cholesterol Levels and Promotes Hepatosteatosis in Hyperlipidemic Mice
por: Vrins, Carlos L. J., et al.
Publicado: (2013)

The Orexin System: A Potential Player in the Pathophysiology of Absence Epilepsy
por: Celli, Roberta, et al.
Publicado: (2022)

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies
por: Brahmer, Julie R., et al.
Publicado: (2020)

Sustained release of the candidate antiretroviral peptides T-1249 and JNJ54310516-AFP from a rod insert vaginal ring
por: Murphy, Diarmaid J., et al.
Publicado: (2016)

Functional cardiac orexin receptors: role of orexin-B/orexin 2 receptor in myocardial protection
por: Patel, Vanlata H., et al.
Publicado: (2018)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

α -decay properties of $^{200,202}$FR
por: Ghys, L, et al.
Publicado: (2019)

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845
por: Vijgen, Leen, et al.
Publicado: (2017)

Dissociating orexin-dependent and -independent functions of orexin neurons using novel Orexin-Flp knock-in mice
por: Chowdhury, Srikanta, et al.
Publicado: (2019)

JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis
por: Heinicke, Ulrike, et al.
Publicado: (2015)

Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2022)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

A study on the effect of JNJ-10397049 on proliferation and differentiation of neural precursor cells
por: Karami, Neda, et al.
Publicado: (2022)

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study( )
por: O’Neil, Brian, et al.
Publicado: (2020)

An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists
por: Chen, Xia, et al.
Publicado: (2012)

Orexin-A and Orexin-B During the Postnatal Development of the Rat Brain
por: Stoyanova, Irina I., et al.
Publicado: (2009)

A photocaged orexin-B for spatiotemporally precise control of orexin signaling
por: Duffet, Loïc, et al.
Publicado: (2022)

Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity
por: Turku, Ainoleena, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_00oku494si3ngps8ej225cpths